Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

Barclays PLC lessened its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 62.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,594 shares of the company’s stock after selling 132,019 shares during the period. Barclays PLC’s holdings in 2seventy bio were worth $380,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Venator Management LLC grew its holdings in shares of 2seventy bio by 49.2% during the 2nd quarter. Venator Management LLC now owns 485,000 shares of the company’s stock worth $1,867,000 after purchasing an additional 160,000 shares in the last quarter. BBR Partners LLC lifted its position in 2seventy bio by 620.0% during the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after purchasing an additional 155,000 shares during the period. GSA Capital Partners LLP acquired a new stake in 2seventy bio during the third quarter worth about $64,000. FMR LLC increased its holdings in 2seventy bio by 22.0% in the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares during the period. Finally, XTX Topco Ltd increased its holdings in 2seventy bio by 61.1% in the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after buying an additional 9,257 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

2seventy bio Trading Down 1.7 %

Shares of 2seventy bio stock opened at $2.91 on Friday. The company has a market cap of $150.12 million, a PE ratio of -1.56 and a beta of 1.69. The company has a 50 day moving average of $3.70 and a 200-day moving average of $4.24. 2seventy bio, Inc. has a 1-year low of $2.78 and a 1-year high of $6.40.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.